{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,11]],"date-time":"2026-03-11T11:57:58Z","timestamp":1773230278762,"version":"3.50.1"},"reference-count":12,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2006,7,1]],"date-time":"2006-07-01T00:00:00Z","timestamp":1151712000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2006,7,1]],"date-time":"2006-07-01T00:00:00Z","timestamp":1151712000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Blood Cells, Molecules, and Diseases"],"published-print":{"date-parts":[[2006,7]]},"DOI":"10.1016\/j.bcmd.2006.05.002","type":"journal-article","created":{"date-parts":[[2006,7,8]],"date-time":"2006-07-08T07:20:27Z","timestamp":1152343227000},"page":"46-49","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"title":["National health budgets for expensive orphan drugs: Gaucher disease in Israel as a model"],"prefix":"10.1016","volume":"37","author":[{"given":"Irina","family":"Kesselman","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Deborah","family":"Elstein","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Avi","family":"Israeli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Raul","family":"Chertkoff","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ari","family":"Zimran","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.bcmd.2006.05.002_bib1","first-page":"473","article-title":"How attractive does a new technology have to be to warrant adoption and utilization? Tentative guidelines for using clinical and economic evaluations","volume":"146","author":"Laupacis","year":"1992","journal-title":"CMAJ"},{"key":"10.1016\/j.bcmd.2006.05.002_bib2","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1093\/qjmed\/91.7.483","article-title":"Low-dose low-frequency imiglucerase as a starting regimen of enzyme replacement therapy for patients with type I Gaucher disease","volume":"91","author":"Elstein","year":"1998","journal-title":"QJM"},{"key":"10.1016\/j.bcmd.2006.05.002_bib3","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1016\/S0140-6736(89)90536-9","article-title":"Prediction of severity of Gaucher's disease by identification of mutations at DNA level","volume":"2","author":"Zimran","year":"1989","journal-title":"Lancet"},{"key":"10.1016\/j.bcmd.2006.05.002_bib4","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1089\/gte.1998.2.297","article-title":"Asymptomatic Gaucher disease implications for large-scale screening","volume":"2","author":"Azuri","year":"1998","journal-title":"Genet. Test"},{"key":"10.1016\/j.bcmd.2006.05.002_bib5","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1046\/j.1365-2141.2000.02177.x","article-title":"Withdrawal of enzyme replacement therapy in Gaucher's disease","volume":"110","author":"Elstein","year":"2000","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.bcmd.2006.05.002_bib6","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1097\/00125817-200211000-00005","article-title":"Cessation of enzyme replacement therapy in Gaucher disease","volume":"4","author":"Grinzaid","year":"2002","journal-title":"Genet. Med."},{"key":"10.1016\/j.bcmd.2006.05.002_bib7","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1111\/j.1365-2141.1993.tb03224.x","article-title":"Low-dose high-frequency enzyme replacement therapy for very young children with severe Gaucher disease","volume":"85","author":"Zimran","year":"1993","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.bcmd.2006.05.002_bib8","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1586\/14737159.4.5.677","article-title":"Diagnosis of lysosomal storage disorders: current techniques and future directions","volume":"4","author":"Meikle","year":"2004","journal-title":"Expert Rev. Mol. Diagn."},{"key":"10.1016\/j.bcmd.2006.05.002_bib9","first-page":"595","article-title":"Managing public payment for high-cost, high-benefit treatment: enzyme replacement therapy for Gaucher's disease in Ontario","volume":"165","author":"Clarke","year":"2001","journal-title":"CMAJ"},{"key":"10.1016\/j.bcmd.2006.05.002_bib10","first-page":"606","article-title":"Management of Gaucher disease in a post-communist transitional health care system: Croatian experience","volume":"44","author":"Mrsic","year":"2003","journal-title":"Croat. Med. J."},{"key":"10.1016\/j.bcmd.2006.05.002_bib11","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1023\/A:1010514614570","article-title":"Neuronopathic Gaucher disease task force of the European Working Group on Gaucher disease. Management of neuronopathic Gaucher disease: a European consensus","volume":"24","author":"Vellodi","year":"2001","journal-title":"J. Inherit. Metab. Dis."},{"key":"10.1016\/j.bcmd.2006.05.002_bib12","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1023\/B:BOLI.0000005619.14180.5c","article-title":"A model of neuronopathic Gaucher disease","volume":"26","author":"Campbell","year":"2003","journal-title":"J. Inherit. Metab. Dis."}],"container-title":["Blood Cells, Molecules, and Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1079979606001276?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1079979606001276?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T12:22:43Z","timestamp":1761049363000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1079979606001276"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,7]]},"references-count":12,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2006,7]]}},"alternative-id":["S1079979606001276"],"URL":"https:\/\/doi.org\/10.1016\/j.bcmd.2006.05.002","relation":{},"ISSN":["1079-9796"],"issn-type":[{"value":"1079-9796","type":"print"}],"subject":[],"published":{"date-parts":[[2006,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"National health budgets for expensive orphan drugs: Gaucher disease in Israel as a model","name":"articletitle","label":"Article Title"},{"value":"Blood Cells, Molecules, and Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bcmd.2006.05.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2006 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}